FDA OK's GSK's Breo in asthmatic adults, not adolescents
This article was originally published in Scrip
Executive Summary
The FDA on 30 April granted approval of GlaxoSmithKline's Breo Ellipta (fluticasone furoate/vilanterol) as a once-daily inhaled treatment for asthma in adults.